Min-Han Tan: The era of liquid biopsy is truly emerging and moving beyond blood
Min-Han Tan, Founding CEO at Lucence, shared a post by Lucence on LinkedIn, adding the following:
“The era of liquid biopsy is truly emerging, and moving beyond blood.
Liquid biopsies using blood are now routine and Medicare-covered for cancer patients.
Conclusive evidence is also available that liquid biopsy NGS is useful for selecting treatments when profiling fluids such as pleural effusion and CSF.
But there’s a big gap to mass cancer screening through blood. Millions of people worldwide are either terrified of blood draw, or not have a convenient facility nearby.
Very glad to partner DxD Hub and Singapore public hospitals in developing a solution to benefit the world!”
Quoting Lucence’s post:
“Screening for multiple cancers using urine can help millions of people who either fear or do not have easy access to phlebotomy.
We’re glad to partner with DxD Hub – Diagnostics Development Hub and Singapore hospitals to expand application of multi-cancer liquid biopsy technology to this important sample type.
Exciting times ahead!”
Source: Min-Han Tan/LinkedIn and Lucence/LinkedIn
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023